February - 2014
| Previous Next | Showing Journal 2 of 11 |
Evaluating the Efficacy and Safety of Two Doses of the Polyclonal Anti-Tumor Necrosis Factor Fragment Antibody AZD9773 in Adult Patients With Severe Sepsis and/or Septic Shock: Randomized, Double-Blind, Placebo-Controlled Phase IIb StudyG Bernard, B Francois, J-P Mira, J-L Vincent, et al Crit Care Med, 2014, 42:504-511 This page is only available to Crit-IQ subscribers. To view the rest of this review and gain access to our vast array of critical care teaching tools including podcasts, vodcasts, modules, exam preparation tools, teaching aids and much more, login here, or Become a Member to register |
February |
Previous Comments
No Comments yet.
Comment
This international, multicenter, DB RCT (phase IIb), randomised 300 patients to placebo or 2-doses of AZD9773 in patients within 24-hours of severe sepsis or septic shock.
AZD9773 is a sheep derived polyclonal Fab fragment combination that acts as a TNF-α blocker, leading to...